Boehringer Ingelheim GmbH Unveils Laval Research Investment; New Jobs

May 28, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Boehringer Ingelheim, one of the world's 20 largest pharmaceutical research and development companies, yesterday unveiled a $36-million research centre in Laval that will specialize in infectious diseases such as Hepatitis C and HIV.

Twitter
LinkedIn
Facebook
Email
Print

Job creations Real estate